Diallyl Trisulfide
Based on 5 publication(s) in Google Scholar
Diallyl Trisulfide is an orally active anticancer agent that can be isolated from garlic. Diallyl Trisulfide has the ability to induce apoptosis and exhibits anticancer, anti-inflammatory, antioxidant, and antibacterial activities. Diallyl Trisulfide can be used to study a variety of cancers, including liver, colon and prostate cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.9%
- CAS. Nr.: 2050-87-5
- Formel: C6H10S3
- Molecular Weight:178.34
-
Speicherung:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-W015635
Diallyl disulfideAnti-inflammatory/Anti-cancer Agent -
HY-N0315
AllicinBacterial Inhibitor -
HY-B0215
AcetylcysteineMucolytic Agent -
HY-13755
SulforaphaneKeap1/Nrf2/ARE Inducer -
HY-Y0873
PEG300Neutral Polymer -
HY-13027
DAPTγ-secretase Inhibitor -
HY-121526
S-Nitroso-N-acetyl-DL-penicillamineNitric oxide donor -
HY-18233
ManogepixAntifungal Agent -
HY-117235R
Diallyl Trisulfide (Standard)Anticancer Agent -
HY-13683
MifepristoneProgesterone Receptor Antagonist -
HY-N0055
Chlorogenic acidAntioxidant -
HY-N0453
HypericinPKC Inhibitor
Publications Citing Use of MedChemExpress (MCE) Diallyl Trisulfide
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Cell Imaging/Staining
-
WB
-
WB
Biologische Aktivität
Beschreibung
IC50 & Target
|
IL-6 |
IL-8 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
0.49 μM
Compound: 4
|
Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels
Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels
|
[PMID: 20356305] |
| MDCK | IC50 |
0.05 mM
Compound: 3
|
Cytotoxicity against MDCK cells assessed as decrease in cell viability after 16 hrs by tetrazolium salt WST-1 assay
Cytotoxicity against MDCK cells assessed as decrease in cell viability after 16 hrs by tetrazolium salt WST-1 assay
|
[PMID: 23163425] |
In Vitro
Diallyl Trisulfide (25-100 μM; 24-72 h) induces apoptosis and inhibits cell proliferation in A549 cells, exhibiting anticancer activity[1].
Diallyl Trisulfide (5-10 μM; 1 h) significantly inhibits naphthalene (20 μM)-stimulated ROS generation and reduces the levels of inflammatory factors IL-6, TNF-α, and IL-8 by increasing superoxide dismutase (SOD) activity, thereby possessing antioxidant and anti-inflammatory activities[2].
Diallyl Trisulfide (93.75-375 µM; 24 h) attenuates H9N2 avian influenza virus (AIV) infection in human lung A549 epithelial cells, demonstrating antiviral activity[3].
Diallyl Trisulfide inhibits the growth of Penicillium expansum with antifungal activity (minimum fungicidal concentration (MFC)99 value: ≤ 90 μg/mL)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549
-
Concentration:75 μM, 93.75 μM, 125 μM, 125 μM, 187.5 μM, 250 μM, 375 μM, 500 μM
-
Incubation Time:48 h
-
Result:Was not cytotoxic to A549 cells.
-
Cell Line:A549
-
Concentration:25 μM, 50 μM, 100 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited cell activity in a dose-dependent manner.
-
Cell Line:A549
-
Concentration:25 μM, 50 μM, 100 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Significantly reduced the expression of Bcl-2 protein at a dose of 100 μM for 48 h.
significantly increased the expression of Bax protein.
-
Cell Line:A549
-
Concentration:100 μM
-
Incubation Time:48 h
-
Result:Increased the mRNA expression of caspase-3, -8, and -9.
Significantly increased the expression of Bax mRNA.
-
Cell Line:A549
-
Concentration:375 µM
-
Incubation Time:24 h, 48 h
-
Result:Increased the expression of antiviral factors RIG-I, IRF-3 and IFN-β.
In Vivo
Diallyl Trisulfide (20-80 mg/kg; Oral gavage, single dose) demonstrates antioxidant and anti-inflammatory activities in Kunming mice induced by naphthalene (100 mg/kg; orally, single dose)[2].
Diallyl Trisulfide (30 mg/kg; intraperitoneal injection; once daily for 2 weeks) reduces lung edema and inflammation caused by H9N2 AIV infection in BABL/c mice, exhibiting antiviral activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mouse model of inflammation induced by naphthalene[2]
-
Dosage:20 mg/kg, 40 mg/kg, 80 mg/kg
-
Administration:Oral gavage (p.o.); Single dose. Before naphthalene treatment (100 mg/kg; p.o., single dose)
-
Result:Inhibited the production of serum nitric oxide (NO) and pulmonary myeloperoxidase (MPO).
Significantly reduced the area of inflammatory cell infiltration induced by naphthalene and alleviated lung injury in mice.
-
Animal Model:BABL/c mice model infected with H9N2 AIV[3]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection (i.p.); Once daily for two weeks
-
Result:Reduced the severity of pulmonary edema.
Significantly reduced viral load in mouse lungs.
Chemical Information
-
CAS. Nr. 2050-87-5
-
Appearance Liquid (Density: 1.085 g/cm3)
-
Molecular Weight 178.34
-
Formel C6H10S3
-
Color Colorless to light yellow
-
SMILES
C=CCSSSCC=C
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
-
-
Front Pharmacol
2022 Feb 15;13:809034. PMID: 35242032
Diallyl Trisulfide purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2022 Feb 15;13:809034. [Abstract]
Effects of different doses of DATS (Diallyl Trisulfide, 0-60 mg/kg) on the survival area on POD 7.
Diallyl Trisulfide purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2022 Feb 15;13:809034. [Abstract]
Digital high-definition photos of flap survival/necrosis area in the control, DATS, and DATS (Diallyl Trisulfide)+3MA groups on the 3rd and 7th PODs.
Diallyl Trisulfide purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2022 Feb 15;13:809034. [Abstract]
Autophagosomes (LCII, red) and nuclei (DAPI, blue) in cells in the choke II zone of flaps in the control, DATS (Diallyl Trisulfide), and DATS+3MA groups.
Diallyl Trisulfide purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2022 Feb 15;13:809034. [Abstract]
Western blotting of autophagy markers, Beclin1, CTSD, LC3II, VPS34, and p62 in the control, DATS (Diallyl Trisulfide), and DATS+3MA groups.
Diallyl Trisulfide purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2022 Feb 15;13:809034. [Abstract]
Western blotting of angiogenesis markers, Cadherin 5, VEGF, and MMP9 in the control, DATS (Diallyl Trisulfide), and DATS+3MA groups. All the gel electrophoresis experiments were carried out under the same experimental conditions.
-
Brain Res
Diallyl trisulfide regulates PGK1/Nrf2 expression and reduces inflammation to alleviate neurological damage in mice after traumatic brain injury. [Abstract]2024 Nov 15:1843:149116. PMID: 38977238 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 50 mg/mL (280.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (7.01 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (7.01 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (421 KB)
- English - EN (421 KB)
- Français - FR (421 KB)
- Deutsch - DE (421 KB)
- Norwegian - NO (421 KB)
- Español - ES (421 KB)
- Swedish - SV (421 KB)
- Italian - IT (421 KB)
- Korean - KR (421 KB)
- Portuguese - PT (421 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Li W, et al. Diallyl trisulfide induces apoptosis and inhibits proliferation of A549 cells in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2012 Jul;44(7):577-83. [Content Brief]
[2]. Zhang F, et al. Diallyl trisulfide inhibits naphthalene-induced oxidative injury and the production of inflammatory responses in A549 cells and mice. Int Immunopharmacol. 2015 Dec;29(2):326-333. [Content Brief]
[3]. Ming L, et al. Antiviral activity of diallyl trisulfide against H9N2 avian influenza virus infection in vitro and in vivo. Virol J. 2021 Aug 19;18(1):171. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.6073 mL | 28.0363 mL | 56.0727 mL | 140.1817 mL |
| 5 mM | 1.1215 mL | 5.6073 mL | 11.2145 mL | 28.0363 mL | |
| 10 mM | 0.5607 mL | 2.8036 mL | 5.6073 mL | 14.0182 mL | |
| 15 mM | 0.3738 mL | 1.8691 mL | 3.7382 mL | 9.3454 mL | |
| 20 mM | 0.2804 mL | 1.4018 mL | 2.8036 mL | 7.0091 mL | |
| 25 mM | 0.2243 mL | 1.1215 mL | 2.2429 mL | 5.6073 mL | |
| 30 mM | 0.1869 mL | 0.9345 mL | 1.8691 mL | 4.6727 mL | |
| 40 mM | 0.1402 mL | 0.7009 mL | 1.4018 mL | 3.5045 mL | |
| 50 mM | 0.1121 mL | 0.5607 mL | 1.1215 mL | 2.8036 mL | |
| 60 mM | 0.0935 mL | 0.4673 mL | 0.9345 mL | 2.3364 mL | |
| 80 mM | 0.0701 mL | 0.3505 mL | 0.7009 mL | 1.7523 mL | |
| 100 mM | 0.0561 mL | 0.2804 mL | 0.5607 mL | 1.4018 mL |
Diallyl Trisulfide Related Classifications
HY-117235 Related Classifications
Powered by Bioz